QuantumPharm Future Growth
Future criteria checks 2/6
QuantumPharm is forecast to grow earnings and revenue by 83.8% and 39.4% per annum respectively. EPS is expected to grow by 91.3% per annum. Return on equity is forecast to be -7.9% in 3 years.
Key information
83.8%
Earnings growth rate
91.3%
EPS growth rate
| Life Sciences earnings growth | 49.5% |
| Revenue growth rate | 39.4% |
| Future return on equity | -7.9% |
| Analyst coverage | Low |
| Last updated | 29 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 845 | -117 | -126 | -71 | 3 |
| 12/31/2025 | 487 | -343 | -306 | -251 | 3 |
| 12/31/2024 | 283 | -644 | -573 | -524 | 3 |
| 6/30/2024 | 197 | -2,538 | -684 | -568 | N/A |
| 3/31/2024 | 186 | -2,226 | -691 | -568 | N/A |
| 12/31/2023 | 174 | -1,914 | -698 | -568 | N/A |
| 12/31/2022 | 133 | -1,439 | -628 | -429 | N/A |
| 12/31/2021 | 63 | -2,137 | -417 | -254 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2228 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2228 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2228 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2228's revenue (39.4% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 2228's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2228 is forecast to be unprofitable in 3 years.